Filing Details

Accession Number:
0000899243-21-034627
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-08-31 19:06:18
Reporting Period:
2021-08-27
Accepted Time:
2021-08-31 19:06:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1435049 Chinook Therapeutics Inc. KDNY Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1745960 Versant Voyageurs I, L.p. One Sansome Street
Suite 3630
San Francisco CA 94104
No No Yes No
1745961 Versant Voyageurs I Parallel, L.p. One Sansome Street
Suite 3630
San Francisco CA 94104
No No Yes No
1750266 Versant Venture Capital Vii, L.p. One Sansome Street
Suite 3630
San Francisco CA 94104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-08-27 510,000 $14.00 4,223,023 No 4 S Direct
Common Stock Disposition 2021-08-27 261,902 $14.00 2,171,197 No 4 S Indirect See Footnote
Common Stock Disposition 2021-08-27 78,098 $14.00 644,149 No 4 S Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Indirect See Footnote
No 4 S Indirect See Footnote
Footnotes
  1. These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Versant VII GP-GP, Versant VII GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
  2. These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis, a member of the Issuer's board of directors, is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Versant Voyageurs I GP Company and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.
  3. These securities are held of record by Versant Voyageurs I Parallel L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis, a member of the Issuer's board of directors, is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Versant Ventures VI GP-GP, Versant Ventures VI GP, Versant Voyageurs I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. Jerel C. Davis is a director of the Issuer and, accordingly, files separate Section 16 reports.